F&P Healthcare: 1H23 Result — Flow Improving
F&P Healthcare's (FPH) 1H23 result confirmed the worst of the COVID crunch is over; the result itself was solid without being spectacular and...
477 Views
F&P Healthcare (FPH): 1H23 Result – Initial Impressions
F&P Healthcare (FPH) reported a 1H23 result at the top end of guidance with NPAT of NZ$95.9m (NZ$85-95m); Revenue of NZ$691m was ahead of guidance...
278 Views
F&P Healthcare: 1H23 Preview — COVID Crunching
Headline numbers were guided in August but we expect F&P Healthcare's (FPH) 1H23 result to show a challenged period highlighting the COVID demand...
263 Views
Equity Strategy: WACC Review — The New Normal?
10 year New Zealand Government bond rates have risen ~+1% since our last WACC review on 13 May 2022, and are up ~+4% since the low in late...
257 Views
F&P Healthcare: Checking the Flow — Competitor Updates
Vapotherm's 3Q22 result continues to reinforce the material headwinds being experienced by F&P Healthcare's (FPH) Hospital segment, particularly...
89 Views